2005-2008

2008
Coming soon

2007
Coming soon

2006
Hodson J, Graham A, Hughes JMB et al. Pulmonary artery-to-artery anastomoses: angiographic demonstration in patients with chronic thromboembolic pulmonary hypertension. Clin Radiol 2006; 61: 259-263.

Ingram W, Desai SR, Gibbs JSR et al. Reduced-intensity conditioned allogeneic haematopoietic transplantation in an adult with Langerhans' cell histiocytosis and thrombocytopenia with absent radii. Bone Marrow Transplant 2006; 37: 713-715.

Thorne S, Nelson-Piercy C, MacGregor A et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension.
J Fam Plann Reprod Health Care 2006; 32: 75-81.

Salam VBA, Paul GA, Ali O et al. Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics 2006; 6(7): 2286-2294.

Machado RD, Koehler R, Glissmeyer E et al. Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 17(7): 793-797.

2005
Aldashev AA, Kojonazarov BK, Amatov TA et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005; 60: 683-687.

Paul GA, Gibbs JS, Boobis AR et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60: 107-112

Wharton J, Strange JW, Moller GM et al. Anti-proliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Am J Respir Crit Care Med 2005; 172: 105-113.

Wilkins MR, Paul GA, Strange JW et al. Sildenafil or endothelin receptor antagonist for pulmonary hypertension. Am J Respir Crit Care Med 2005; 171: 1292-1297.

Khoo J, Zhao L, Wilkins MR et al. A pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 2005; 111: 2126-2133.

Phillips PG, Long L, Wilkins MR et al. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol 2005; 288: L103-115.

Gatzoulis MA, Rogers P, Li W et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005; 98: 147-151.

le Roux CW, Ghatei MA, Gibbs JSR et al. The putative satiety hormone, PYY, is elevated in cardiac cachexia associated with primary pulmonary hypertension. Heart 2005; 91: 61-66.

Wright MJ, Gibbs JSR. Oral treatments for pulmonary arterial hypertension. Br J Cardiol (Acute Interv Cardiol) 2005; 12: AIC62-AIC67.

Gibbs JSR. Pulmonary hypertension. In: Horizons in Medicine 17. Haskard D, ed. London: Royal College of Physicians, 2005. 121-127.